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Drs Godman and Fadare review the paper by Mares-Garcia and colleagues in Spain regarding the 
extent of non-guideline recommended prescribing (NGRP) of proton pump inhibitors (PPIs) in 
ambulatory care. NGRP of PPIs is an increasing public health concern given the implications of 
overuse of PPIs on infection rates, osteoporosis and chronic kidney disease as well as increasing 
polypharmacy rates. Costs are less of an issue especially where there are low prices for generic PPIs; 
the main focus is on improving the quality of PPI prescribing. Encouragingly, Mares-Garcia and 
colleagues identified key factors associated with NGRP, providing direction to others. 
 




Mares-Garcia and colleagues are to be congratulated on their recent paper regarding the non-
guideline recommended prescribing (NGRP) of proton pump inhibitors (PPIs) in ambulatory care in 
one of the Spanish provinces (Alicante) (1). In addition, documenting the costs associated with NGRP 
of PPIs, which has typically not been examined before. This is particularly important as most studies 
assessing the extent of NGRP PPI prescribing have concentrated on hospitals (1); however, the vast 
majority of PPI prescriptions are for ambulatory care patients. 
 
The authors used a robust approach to examine the extent of PPI NGRP(1). This involved electronic 
prescribing, which in Spain includes diagnosis information. This combined information helps 
healthcare professionals, including health authority personnel, assess their prescribing against current 
guidance as a basis for future improvement. Similar combined information  is also available in other 
Spanish regions as well as in other countries to enhance the future quality of prescribing (2, 3). These 
combined data sets are particularly helpful in this situation to enable an accurate assessment of 
NGRP versus perceptions. This is important as compliance with guidelines is variable across 
countries (4-8), which compliance enhanced by the instigation of multifaceted approaches, reminders 
and the involvement of key personnel in those developing the guidance (2, 3, 9, 10).  
 
The authors point out that the utilisation of PPIs has increased appreciably in recent years across 
countries, with PPIs becoming the most prescribed medicine by volume in Spain in recent years. All 
age groups appear involved with increasing utilisation rates (11). Considerable growth rates in the 
precribing of PPIs have been seen in other European countries especially Western European 
countries (12-14). Despite this appreciably increased utilisation of PPIs in Europe, expenditure  has 
fallen in recent years and is  now lower  in a number of countries than before generic PPUs became 
available. This has been helped bycountries encouraging the preferential prescribing of low cost 
generic PPIs versus patented PPIs with no perceived differences in effectiveness between the various 
PPIs (12-15).  Prices of generic omeprazole have been as low as 2% of pre-patent loss prices in 
some European countries (12) further lowering expenditure, with low prices also seen in Spain but not 
as low as 2% of pre-patent loss prices(1).  
 
Unfortunately, these low prices for generic PPIs, as well as lower expenditure in recent years, may 
well have resulted in health authorities and physicians paying less attention regarding the quality and 
efficiency of PPI prescribing. This compares with other high volume classes of medicines in 
ambulatory care where patented products are still available, which appreciably increase costs if 
preferentially prescribed versus generics with no obvious patient benefits. This included the statins, 
until generic atorvastatin became available, as well as the angiotensin receptor blockers once 
generics became available (15, 16). However, savings can only be made if physicians trust the quality 
of available generics, which is less of an issue in Europe compared with a number of lower and 
middle income countries (17-19). Physicians in a number of countries, including European 
countries,are encouraged via health authorities or education starting in medical schools to enhance 
their prescribing of generics, combating the activities of pharmaceutical companies (14, 20, 21). 
 
This is now changing., As Mares-Garcia and colleagues pointed out, there is now increasing scrutiny 
regarding the prescribing of PPIs in ambulatory care, especially in Western countries, with concerns 
regarding their over use. Potential over use of PPIs was seen in their study, with 122 patients older 
than 60 out of 302 patients studied having no obvious reason for being prescribed PPIs; similarly 70 
patients under 60 had no risk factors for upper GI bleeding (1). This is perhaps not surprising since 
many physicians prescribe PPIs prophylactically for elderly patients with conditions such as 
osteoporosis without adequate risk stratification (22, 23). Over use of PPIs can increase the extent of 
polypharmacy, leading to concerns with adherence and drug: drug interactions (24, 25). In addition, 
increasing the risk of infection, osteoporosis (11, 26-31) and chronic kidney disease (32, 33), although 
there is some controversy (34). These concerns have resulted in calls to educate both ambulatory 
care physicians and specialists on appropriate PPI use (35). This includes using the lowest effective 
dose where PPIs cannot be avoided and reducing prescribing generally in low risk patients (31, 35).  
 
Encouragingly, Mares-Garcia and colleagues identified key factors associated with NGRP of PPIs. 
Identifying such risk factors can help researchers and health authorities target efficiently at-risk 
prescribers of PPIs and subsequently implement targeted preventative educational programmes. . 
The alternative is to restrict prescribing of PPIs to targeted indications, with 100% co-payments for 
non-reimbursed indications. In for instance in Lithuania, PPIs have a 50% co-payment for 
reimbursement, with reimbursement restricted to patients with reflux oesophagitis, duodenal ulcers, or 
for Helicobacter pylori eradication (36). This appreciably reduced their reimbursed prescribing to one 
twentieth to one thirtieth of that seen among Western European, although higher utilisation rates are 
seen once self-purchasing is included (12, 36, 37). However, prescribing restrictions are not always 
possible, with a combination of physician education, agreed quality targets and financial incentives 
equally effective in achieving changes in physician prescribing behaviour (13, 14, 37, 38). This is the 
suggested approach in this situation.    
 
Finally, whilst the authors highlight the acquisition costs of NGRP, this is perhaps less of an issue 
among Western countries if the cost of PPIs dispensed is Euro1/ month as seen for instance in the 
Netherlands (12). As discussed, the higher public health priority surrounds the appropriateness of PPI 
prescribing and the clinical implications associated with their over use as highlighted by the authors in 
their introduction (1). This includes patients with osteoarthritis as well as those with multiple co-
morbidities (1).  
 
The authors conclude that their analysis provides good insight into current PPI prescribing and 
associated factors with NGRP in Spain. Their analysis can help guide future prescribing of PPIs in 
ambulatory care in Spain and generally among Western countries, with all physicians beholden to 
improve the judicious use of these medicines. 
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